What is BeyondSpring Inc?
BeyondSpring Inc. is a clinical-stage biopharmaceutical enterprise headquartered in Florham Park, New Jersey, dedicated to the innovation of cancer therapies. The company's primary focus centers on Plinabulin, a selective immunomodulating microtubule-binding agent currently undergoing rigorous evaluation for non-small cell lung cancer and chemotherapy-induced neutropenia. Beyond its lead asset, the firm maintains a diverse pipeline that includes small molecule immune agents and collaborative drug discovery efforts. By integrating immuno-oncology agents with established chemotherapy protocols, BeyondSpring aims to redefine standard-of-care paradigms in the treatment of complex malignancies.
How much funding has BeyondSpring Inc raised?
BeyondSpring Inc has raised a total of $3.8M across 2 funding rounds:
Stock Offering
$3.5M
Debt
$350K
Stock Issuance/Offering (2017): $3.5M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Key Investors in BeyondSpring Inc
PPP
Public-Private Partnership
Undisclosed Investor
A strategic participant in the company's stock issuance, contributing to the overall capital structure required for late-stage drug development.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the advancement of the company's oncology pipeline.
What's next for BeyondSpring Inc?
Looking ahead, BeyondSpring Inc. is positioned to leverage its recent financing to accelerate Phase III clinical trials and expand its combination therapy portfolio. The strategic deployment of these funds will likely prioritize the advancement of Plinabulin in conjunction with PD-1 and CTLA-4 antibodies, aiming to enhance efficacy in extensive-stage small cell lung cancer. Furthermore, the company is expected to scale its internal research capabilities, focusing on the maturation of its preclinical small molecule pipeline. As the firm navigates the regulatory landscape, the focus will remain on achieving key clinical milestones that validate its therapeutic platform and drive long-term shareholder value in the global oncology market.
See full BeyondSpring Inc company page
